Tag Archives: Eagle Pharmaceuticals

RBC Capital Sticks to Their Buy Rating for Eagle Pharmaceuticals

In a report released today, Randall Stanicky from RBC Capital reiterated a Buy rating on Eagle Pharmaceuticals (NASDAQ: EGRX), with a price target of $75. The company’s shares opened today at $56.69. According to TipRanks.com, Stanicky is ranked 0 out

Eagle Pharmaceuticals Receives a Sell from Mizuho Securities

In a report released today, Irina Rivkind Koffler from Mizuho Securities assigned a Sell rating to Eagle Pharmaceuticals (NASDAQ: EGRX), with a price target of $37. The company’s shares opened today at $59.68. Rivkind Koffler said: “We view both these

Piper Jaffray Sticks to Their Buy Rating for Eagle Pharmaceuticals

Piper Jaffray analyst David Amsellem reiterated a Buy rating on Eagle Pharmaceuticals (NASDAQ: EGRX) on October 24 and set a price target of $75. The company’s shares closed yesterday at $54.08. According to TipRanks.com, Amsellem is a 1-star analyst with

Eagle Pharmaceuticals Receives a New Rating from Top Analyst

Mizuho Securities analyst Irina Rivkind Koffler reiterated a Sell rating on Eagle Pharmaceuticals (NASDAQ: EGRX) today. The company’s shares opened today at $75.43. Rivkind Koffler commented: “We raise our PT on EGRX to $66 from $64 and reiterate our Underperform

Analysts Offer Insights on Healthcare Companies: Eagle Pharmaceuticals (NASDAQ: EGRX), Akari Therapeutics PLC (ADR) (NASDAQ: AKTX) and Alnylam Pharmaceuticals (NASDAQ: ALNY)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Eagle Pharmaceuticals (NASDAQ: EGRX), Akari Therapeutics PLC (ADR) (NASDAQ: AKTX) and Alnylam Pharmaceuticals (NASDAQ: ALNY). Eagle Pharmaceuticals (NASDAQ: EGRX) In a report released

Mizuho Securities Thinks Eagle Pharmaceuticals’ Stock is Going to Recover

According to The Fly, mizuho Securities analyst Irina Rivkind Koffler reiterated a Buy rating on Eagle Pharmaceuticals (NASDAQ: EGRX) today and set a price target of $71. The company’s shares opened today at $36.04, close to its 52-week low of